




RealRate

PHARMACEUTICAL 2020

Moleculin Biotech Inc.
Rank 199 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Moleculin Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Moleculin Biotech Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 160% points. The greatest weakness of Moleculin Biotech Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 130% points.

The company's Economic Capital Ratio, given in the ranking table, is -209%, being 94% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	13,484
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,570
Liabilities, Non-Current	276
Other Assets	11,435
Other Compr. Net Income	-4.0
Other Expenses	-4,092
Other Liabilities	5,818
Other Net Income	28
Property and Equipment	316
Research and Development	11,013
Revenues	0
Selling, General and Administrative Expense	6,312

Output Variable	Value in 1000 USD
Assets	25,235
Liabilities	9,664
Expenses	13,233
Stockholders Equity	15,571
Net Income	-13,205
Comprehensive Net Income	-13,207
Economic Capital Ratio	-209%